Als donateur kunt u korting krijgen.

Voor OriVeda, voor uitstekende kwaliteit medicinale paddestoelextracten. zie dit artikel en klik door op de link daar: https://kanker-actueel.nl/ops-korting-oriveda-geeft-25-procent-korting-op-extracten-van-medicinale-paddenstoelen-aan-ops-donateurs-van-kanker-actueel.html

9 mei 2022: In onderstaand artikel een fout in dosering gecorrigeerd en wat links naar studierapporten toegevoegd plus referentielijst van 53 andere studies.

En deze recente studie toegevoegd. Abstract staat verderop in artikel:

de werkzaamheid van Papilocare, een op Coriolus versicolor gebaseerde vaginale gel, bij het herstellen van aan het humaan papillomavirus (HPV) gerelateerde laaggradige baarmoederhals afwijkingen / tumoren geeft uitstekende resultaten blijkt uit de PALOMA studie.

Dit is de titel van de studie uit 2021:

Efficacy of a Coriolus versicolor–Based Vaginal Gel in Women With Human Papillomavirus–Dependent Cervical Lesions: The PALOMA Study

Vertaling van de resultaten:

Het percentage patiënten met een normaal uitstrijkje en bevestigd door coloscopie 3 en 6 maanden na behandeling (78,0% en 84,9%) was significant hoger dan zonder behandeling (54,8% en 64,5%), vooral bij hoog-risico HPV-patiënten (79,5% en 87,8% versus 52,0% en 56,0%).
Na een bezoek van 6 maanden werd de algehele HPV-klaring bereikt door een groter aantal patiënten dat werd behandeld (59,6%) in vergelijking met degenen zonder behandeling (41,9%), vooral bij HPV-patiënten met een hoog risico (62,5% versus 40,0%).
De cervicale re-epithelisatiescore was significant hoger met behandeling (gemiddelde = 4,5) dan zonder (gemiddelde = 4,1).
Vergeleken met baseline nam de waargenomen stress af in de behandelingsgroep (van 21,1 naar 19,0) en nam toe in de controlegroep (van 17,7 naar 20,7).
Er werden in totaal 7 mogelijke of waarschijnlijke behandelingsgerelateerde bijwerkingen gemeld, waarvan de meeste (n = 6) licht of matig van ernst waren.

Hier het studieprotocol van de PALOMA studie.

Lees ook deze reviewstudie:

626 Efficacy of a multi-ingredient coriolus versicolor-based vaginal gel in high-risk HPV infected patients: results of 7 different studies

9 augustus 2009: Bron: Tijdschrift Mycologyresearch

Suppletie met de medicinale paddestoel Coriolus Versicolor (5 gram dagelijks in tabletvorm) geeft hoog significant effect op verdwijnen van HPV virus bij baarmoederhalskankerpatienten met beginnende kanker. De paddestoelen doen ook tumoren slinken en graad van kwaadaardigheid veranderen in minder kwaadaardigheid. Dit blijkt uit de resultaten van een gerandomiseerde studie van 1 jaar bij patienten met beginnende baarmoederhalskanker. Het HPV virus was na 1 jaar bij 91% van de deelnemers verdwenen t.o.v. 8,5% bij de controlegroep die geen suppletie kregen.. De Coriolus Versicolor kan dus een uitstekend alternatief zijn voor vaccinatie tegen het HPV virus. En goedkoper en veiliger. Voor OPS donateurs hebben we het volledige studierapport beschikbaar waarin ook de werkzame dosis en het procces hoe het werkt beschreven staat. Hier een aantal citaten uit het volledige studierapport geciteerd en met hulp van google vertaald. Het studierapport bevat ook beschrijvingen van andere studies met soorgelijke positieve resultaten van medicinale paddestoelen. Zie onderaan titels van studies

De resultaten van een gerandomiseerde klinische studie welke de effecten van paddestoelen suppletie (Coriolus Versicolor) een jaar lang onderzocht bij patiënten met het Human Papilloma Virus (HPV) en beginstadium van baarmoederhalskanker zijn onlangs gepresenteerd. Dr. Jose Silva Couto en Dr. Daniel Pereira da Silva of the Cervical Pathology Unit van het Portuguese Institute of Oncology in Coimbra, Portugal presenteerden hun bevindingen op het 20e Europese Congres van Obstetrics en Gynaecology, in Lisabon Portugal. Deze studie biedt veelbelovende resultaten en toont het bewijs op de vraag of voedingssupplementen met succes ingezet kunnen worden bij immuuntherapie voor het verbeteren van de HPV-status bij patiënten met beginnende baarmoederhalskanker.

Wat betekenen deze resultaten voor HPV-patiënten?
De resultaten van deze studie zijn bemoedigend en geven inzicht in de effectiviteit van Coriolus versicolor als een nuttig immuuntherapeutisch voedingsmedicijn. Met behulp van de Coriolus Versicolor suppletie van een jaar lang resulteerde erin dat 72,5% van de patienten die de suppletie kregen terugkeerden naar normale cytologie status vergeleken met slechts 47,5% van de controlegroep (zonder supplementen). Hoopvol is dat 91,5% van de Coriolus Versicolor ontvangers een normale HPV-status terugkregen in vergelijking met slechts 8,5% in de controlegroep.
Simpel gesteld de huid textuur van het cervicale gebied kwam weer op een normaal niveau bij 72,5% van de patiënten die de Coriolus suppletie namen, terwijl de virale belasting van het HPV virus niet meer werd aangetroffen (0) in 91,5% van de patiënten die de Coriolus suppletie kregen. Gezien het feit dat het HPV-virus verantwoordelijk is voor de cervicale laesies (kwaadaardige polipeen en tumoren, wordt de impact van de Coriolus suppletie op HPV viral load reductie significant geacht.

With

Coriolus versicolor

Without supplementation

Total

TABLE 1		Negative after 1 year		Positive after 1 year		Negative after 1 year		Positive after 1 year
Citology	13 (72.5%)		5 (27.5%)		10 (47,5%)		11 (52.5%)		39
HPV	9 (91.5%)		1 (10%)		1 (8,5%)		11 (91.5%)		22

2021 Apr; 25(2): 130–136.

Published online 2021 Mar 22. doi: 10.1097/LGT.0000000000000596

PMCID: PMC7984756

PMID: 33746195

Efficacy of a Coriolus versicolor–Based Vaginal Gel in Women With Human Papillomavirus–Dependent Cervical Lesions: The PALOMA Study

Luis Serrano, MD,1 Andrés Carlos López, MD,2 Silvia P. González, MD,1 Santiago Palacios, MD,3 Damián Dexeus, MD,4 Cristina Centeno-Mediavilla, MD, PhD,5 Pluvio Coronado, MD,6 Jesús de la Fuente, MD,7 José Antonio López, MD,8 Cristina Vanrell, MD,9 and Javier Cortés, MD, PhD10

Author information Copyright and License information Disclaimer

Objective

The aim of the study was to evaluate the efficacy of Papilocare, a Coriolus versicolor–based vaginal gel, in repairing human papillomavirus (HPV)-related low-grade cervical lesions.

Methods

The study is a multicenter, open-label, randomized, parallel-group, watchful waiting approach-controlled trial involving 91 HPV-positive women with low-grade Pap smear alterations and consistent colposcopy.

Results

The percentage of patients with normal Pap smear and concordant colposcopy 3 and 6 months after receiving treatment (78.0% and 84.9%) was significantly higher than without treatment (54.8% and 64.5%), especially in high-risk HPV patients (79.5% and 87.8% vs 52.0% and 56.0%). At 6-month visit, overall HPV clearance was achieved by a greater number of patients receiving treatment (59.6%) compared with those without treatment (41.9%), especially high-risk HPV ones (62.5% vs 40.0%). The cervical re-epithelization score was significantly higher with treatment (mean = 4.5) than without (mean = 4.1). Compared with baseline, perceived stress decreased in the treatment group (from 21.1 to 19.0) and increased in the control group (from 17.7 to 20.7). A total of 7 possible or probable treatment-related adverse events were reported, most of them (n = 6) being mild or moderate in severity.

Conclusions

Treatment with Papilocare has demonstrated a better clinical benefit than the conventional watchful waiting approach in clinical practice for total and high-risk HPV patients in terms of its efficacy to treat HPV-related cervical lesions and to clear all HPV strains after a single 6-month period. It has demonstrated an adequate safety and tolerability and confers additional benefits such as higher re-epithelization, stress reduction, and high treatment adherence.

REFERENCES

1. World Health Organization . Human papillomavirus (HPV) and cervical cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer. Accessed May 21, 2020.

2. Ho GY Bierman R Beardsley L, et al. . Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–8. [PubMed] [Google Scholar]

3. McBride E Tatar O Rosberger Z, et al. . Emotional response to testing positive for human papillomavirus at cervical cancer screening: a mixed method systematic review with meta-analysis. Health Psychol Rev 2020;1–35. [PubMed] [Google Scholar]

4. Thangarajah F Einzmann T Bergauer F, et al. . Cervical screening program and the psychological impact of an abnormal Pap smear: a self-assessment questionnaire study of 590 patients. Arch Gynecol Obstet 2016;293:391–8. [PubMed] [Google Scholar]

5. Need for safe, non-surgical treatment for clearing human papilloma virus (HPV). Available at : https://livbio.co.uk/need-for-safe-non-surgical-treatment-for-clearing-human-papilloma-virus-hpv/. Accessed September 17, 2020.

6. Lee JH Kim HL Lee MH, et al. . Asiaticoside enhances normal human skin cell migration, attachment and growth in vitro wound healing model. Phytomedicine 2012;19:1223–7. [PubMed] [Google Scholar]

7. Møller MS Goh YJ Viborg AH, et al. . Recent insight in α-glucan metabolism in probiotic bacteria. Biologia 2014;69:713–21. [Google Scholar]

8. Couto S. Evaluation of Coriolus versicolor supplementation in HPV patients. Clin J of Mycology 2007;2:2–5. [Google Scholar]

9. Shukla S Bharti AC Hussain S, et al. . Elimination of high-risk human papillomavirus type HPV16 infection by ‘Praneem’ polyherbal tablet in women with early cervical intraepithelial lesions. J Cancer Res Clin Oncol 2009;135:1701–9. [PubMed] [Google Scholar]

10. Scardamaglia P Carraro C Mancino P, et al. . Efficacia del carbossimetilbetaglucano nella regressione delle alterazioni citologiche cervicali di basso grado HPV correlate. Minerva Ginecol 2010;62:389–94. [PubMed] [Google Scholar]

11. Egawa N Egawa K Griffin H, et al. . Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses 2015;7:3863–90. [PMC free article] [PubMed] [Google Scholar]

12. Mitra A MacIntyre DA Lee YS, et al. . Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. Sci Rep 2015;5:16865. [PMC free article] [PubMed] [Google Scholar]

13. Audirac-Chalifour A Torres-Poveda K Bahena-Román M, et al. . Cervical microbiome and cytokine profile at various stages of cervical cancer: a pilot study. PLoS One 2016;11:e0153274. [PMC free article] [PubMed] [Google Scholar]

14. Kyrgiou M, Mitra A, Moscicki AB. Does the vaginal microbiota play a role in the development of cervical cancer? Transl Res 2017;179:168–82. [PMC free article] [PubMed] [Google Scholar]

15. Palacios S Losa F Dexeus D, et al. . Beneficial effects of a Coriolus versicolor-based vaginal gel on cervical epithelization, vaginal microbiota and vaginal health: a pilot study in asymptomatic women. BMC Womens Health 2017;17:21. [PMC free article] [PubMed] [Google Scholar]

16. Galvez J Rodríguez Nogales A Vezza T, et al. . Effect of a non-hormonal Coriolus versicolor vaginal gel among positive-HPV women with no colposcopy cervical lesions. A pilot study. Poster presentation. European Research Organization on Genital Infection and Neoplasia (EUROGIN). Amsterdam, October 8–11, 2017. Available at: https://secure.key4events.com/key4register/AbstractList.aspx?e=612&preview=1&aig=-1&ai=15955. Accessed May 21, 2020.

17. Gaslain Y Cortés J Dexeus D, et al. . Evaluation of the immunomodulatory properties of a Coriolus versicolor-based vaginal gel in an in vitro human vaginal epithelium model test. Cape Town: Poster presentation at the 31st International Papillomavirus Conference. International Papillomavirus Society; February 28–March 4, 2017. [Google Scholar]

18. Gálvez J Vezza T Garrido-Mesa J, et al. . Evaluation of the immunomodulatory properties of a Coriolus versicolor-based gel after its topical administration in the vagina of mice. Lisbon: Poster presented at the 30th International Papilomavirus Conference. International Papillomavirus Society; September 17–21, 2015. [Google Scholar]

19. Gálvez J Vezza T Garrido-Mesa J, et al. . Comparative study of the immunomodulatory properties of different Coriolus versicolor-based formulations administered orally or topically in the vagina in healthy mice. Abstract. European Research Organization on Genital Infection and Neoplasia (EUROGIN). Salzburg, June 15–18, 2016. Available at: https://www.eurogin.com/content/dam/Informa/eurogin/previous/EUROGIN-2016.pdf. Accessed May 21, 2020.

20. Solomon D Dravey D Kurman R, et al. Forum Group Members; Bethesda 2001 Workshop . The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002;287:2114–9. [PubMed] [Google Scholar]

21. Bornstein J Bentley J Bösze P, et al. . 2011 Colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol 2012;120:166–72. [PubMed] [Google Scholar]

22. Bachmann GA Notelovitz M Kelly SJ, et al. . Long term nonhormonal treatment of vaginal dryness. Clin Pract Sexuality 1992;8:3–8. [Google Scholar]

23. Remor E. Psychometric properties of a European Spanish version of the Perceived Stress Scale (PSS). Span J Psychol 2006;9:86–93. [PubMed] [Google Scholar]

24. European Medicines Agency . ICH E9 statistical principles for clinical trials. September 1998 CPMP/ICH/363/96. Available at: https://www.ema.europa.eu/en/ich-e9-statistical-principles-clinical-trials. Accessed September 17, 2020.

25. Castellsagué X Iftner T Roura E, et al. . Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE study. J Med Virol 2012;84:947–56. [PubMed] [Google Scholar]

26. Muñoz N Méndez F Posso H, et al. . Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004;190:2077–87. [PubMed] [Google Scholar]

27. Walboomers JM Jacobs MV Manos MM, et al. . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–9. [PubMed] [Google Scholar]

28. World Health Organization . WHO Director-General calls for all countries to take action to help end the suffering caused by cervical cancer. Available at: https://www.who.int/reproductivehealth/call-to-action-elimination-cervical-cancer/en/. Accessed May 21, 2020.

29. Darragh TM Colgan TJ Cox JT, et al. . The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012;16:205–42. [PubMed] [Google Scholar]

30. Matsumoto K Oki A Furuta R, et al. . Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: a prospective cohort study. Int J Cancer 2011;128:2898–910. [PubMed] [Google Scholar]

31. Kyrgiou M Athanasiou A Kalliala IEJ, et al. . Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev 2017;11:CD012847. [PMC free article] [PubMed] [Google Scholar]

32. Torné A del Pino M Cusidó M, et al. . Guía de cribado del cáncer de cuello de útero en España, 2014. Prog Obstet Ginecol 2014;57:1–53. [Google Scholar]

33. Spanish Ministry of Health . Population screening plans in cancer. Available at: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/cribadoCancer.htm. Accessed May 21, 2020.

34. Bulkmans NW Berkhof J Bulk S, et al. POBASCAM Study Group . High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007;96:1419–24. [PMC free article] [PubMed] [Google Scholar]

35. Marín Ortiz E Vázquez Caamaño MP Porto Quintans M, et al. . Efficacy of a Coriolus versicolor-based vaginal gel in high-risk HPV+ women. Preliminary results . Sydney: 32nd International Papillomavirus Conference, IPVC, October 2–6, 2018. Available at: https://ipvc2018.org/PublishingImages/abstract-information/ipvc-2018-submitted-abstracts/IPVC18_-_All_abstracts_for_website.pdf. Accessed May 21, 2020. [Google Scholar]

36. Gajino Suárez C. Use and results of a Coriolus versicolor-based vaginal gel in women HPV+ and/or abnormal pap smear attended in a regional Spanish hospital. Preliminary analysis . Sydney: 32nd International Papillomavirus Conference, IPVC, October 2-6, 2018. Available at: https://ipvc2018.org/PublishingImages/abstract-information/ipvc-2018-submitted-abstracts/IPVC18_-_All_abstracts_for_website.pdf. Accessed May 21, 2020. [Google Scholar]

37. Riera M Rupérez B Lázaro I, et al. . Coriolus versicolor vaginal gel in the treatment of high-risk positive HPV patients . European Research Organization on Genital Infection and Neoplasia (EUROGIN); December 2–5, 2018; Lisbon. Available at: https://www.eurogin.com/content/dam/Informa/eurogin/2018/pdf/Abstracts-Part3.pdf. Accessed May 21, 2020. [Google Scholar]

38. Riera M Rupérez B Lázaro I, et al. . Effect of a multi-ingredient vaginal gel on clearance and/or cytology normalization in high-risk HPV positive patients . J Low Genit Tract Dis 2020;24:16. [Google Scholar]

39. Cortés J de Santiago J Cos A, et al. . Efficacy of a multi-ingredient vaginal gel in repairing HPV-dependent cervical lesions in real-life: interim analysis. Poster presented at the ASCCP, Scientific Meeting on Anogenital & HPV-Related Diseases; March 31–April 3, 2020. Orlando, FL. [Google Scholar]

40. Gaslain Y Cortés J Dexeus D, et al. . Effect of a multi-ingredient vaginal gel in high-risk HPV infected patients: results of different studies. J Low Genit Tract Dis 2020;24:15–6. [Google Scholar]

41. Muñoz N Castellsagué X de González AB, et al. . Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24(suppl 3):S3/1–10. [PubMed] [Google Scholar]

42. Curry SJ Krist AH Owens DK, et al. US Preventive Services Task Force . Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA 2018;320:674–86. [PubMed] [Google Scholar]

43. Venetianer R Clarke MA van der Marel J, et al. . Identification of HPV genotypes causing cervical precancer using tissue-based genotyping. Int J Cancer 2020;146:2836–44. [PubMed] [Google Scholar]

Referentielijst behorend bij studie uit 2009:

Mushroom Nutrition as a Target for Novel Therapeutic Strategies: Relevance to Nutritional Approaches and Antioxidant Redox Modulation in Antiaging Medicine

Calabrese V.

1, Cornelius C.1, Cavallaro M.1, Cambria M.1, Toscano MA2(1) Department of Chemistry and (2) Department of Microbiological Sciences, University of Catania, 95100 Catania, Italy.

— Page 2

Comparative Enzyme Analysis of Polyporus umbellatus, Agaricus blazei , Pleurotus osteratus and Hericium erinaceus.

Cornelius C.

1, Cavallaro M.1, Cambria M.T.1 Toscano M.A.2 and Calabrese V.1(1) Department of Chemistry and (2) Department of Microbiological Sciences, University of Catania, 95100 Catania, Italy.

— Page 5

Coriolus versicolor

Supplementation as Immunonutrition in HPV Patients with Cervical Lesions (LSIL)

Silva Couto, J. , Pereira da Silva , DGynaecology Department – Cervical Pathology Unit, Portuguese Institute of Oncology, 3000 – 075 Coimbra, Portugal.

References:

1. Angelova M, Dolashka-Angelova P, Ivanova E, Serkedjieva J, Slokoska L, Pashova S, Toshkova R, Vassilev S, Simeonov I, Hartmann HJ, Stoeva S, Weser U, Voelter W. (2001) A novel glycosylated Cu/Zn-containing superoxide dismutase: production and potential therapeutic effect. Microbiology 147, 1641- 1640.

2. Harhaji Lj, Mijatovi, S, Maksimovi-Ivani. D, Stojanovi. I, Momcilovi. M, Maksimovi. V, Tufegdzi. S, Marjanovi. Z, Mostarica-Stojkovi. M, Vucini. Z. Stosi.- Grujici. S. (2008) Anti-tumor effect of Coriolus versicolor methanol extract against mouse B16 melanoma cells: in vitro and in vivo study. Food Chem Toxicol 46, 1825-1833.

3. Borchers AT, Krishnamurthy A, Keen CL, Meyers FJ, Gershwin ME. (2008) The immunobiology of mushrooms. Exp. Biol. Med. 233, 259-276.

4. Calabrese V., Bates T.E., Mancuso C., Cornelius C., Ventimiglia B., Cambria M.T., Di Renzo L., De Lorenzo A., Dinkova-Kostova A.T. (2008) Curcumin and the cellular stress response in free radical-related diseases. Mol. Nutr. Food Res. 52, 1062-1073.

5. Calabrese V., Calafato S., Puleo E., Cornelius C., Sapienza M., Morganti P., Mancuso C. (2008) Redox regulation of cellular stress response by ferulic acid ethyl ester in human dermal fibroblasts: role of vitagenes. Clin. Dermatol. 26, 358-363.

6. Halliwell B. (2008) Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies? Arch Biochem Biophys. 476, 107-112.

7. Calabrese V., Scapagnini G., Colombrita C., Ravagna A., Pennisi G., Giuffrida Stella A.M., Galli F., Butterfield D.A. (2003) Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: A nutritional approach. Amino Acids 25:437-444.

8. Poon H.F., Calabrese V., Scapagnini G., Butterfield D.A. (2004) Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. J. Gerontology 59:478-493.

9. Forman H.J., Fukuto J.M., Torres M. (2004) Redox signaling: thiol chemistry defines which reactive oxygen and nitrogen species can act as second messengers. Am J Physiol Cell Physiol. 287:246-256.

10. Poon H.F., Calabrese V., Scapagnini G., Butterfield D.A. (2004) Free radicals and brain aging. Clin. Geriatr. Med. 20:329-359.

11. Calabrese V., Scapagnini G., Ravagna A., Colombrita C., Spadaro F., Butterfield D.A., Giuffrida Stella A.M. (2004) Increased expression of heat shock proteins in rat brain during aging: relationship with mitochondrial function and glutathione redox state. Mech. Age Dev. 125:325-335.

12. Calabrese V., Giuffrida Stella A.M., Butterfield D.A., Scapagnini G. (2004) Redox Regulation in Neurodegeneration and Longevity: Role of the Heme Oxygenase and HSP70 Systems in Brain Stress Tolerance. Antioxid Redox Signal. 6:895-913.

13. Halliwell B. (2002) Hypothesis: proteasomal dysfunction: a primary event in neurogeneration that leads to nitrative and oxidative stress and subsequent cell death. Ann. N. Y. Acad. Sci. 962:182-194.

14. Martindale J.L., Holbrook N.J. (2002) Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol. 192:1-15.

15. Bergamini C.M., Gambetti S., Dondi A., Cervellati C. (2004) Oxygen, reactive oxygen species and tissue damage. Curr. Pharm. Des. 10:1611-1626.

16. Pappolla M.A., Chyan Y.J., Omar R.A., Hsiao K., Perry G., Smith M.A., Bozner P. (1998) Evidence of oxidative stress and in vivo neurotoxicity of betaamyloid in a transgenic mouse model of Alzheimer’s disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 152:871-877.

17. Smith M.A., Hirai K., Hsiao K., Pappolla M.A., Harris P.L., Siedlak S.L., Tabaton M., Perry G. (1998) Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70:2212-2215.

18. Butterfield D.A., Drake J., Pocernich C., Castegna A. (2001) Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid betapeptide. Trends Mol. Med. 7:548-554.

19. Butterfield D.A., Lauderback C.M. (2002) Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress. Free Rad. Biol. Med. 32:1050-1060.

20. Mattson M.P. (2004) Pathways towards and away from Alzheimer’s disease. Nature 430:631-639.

21. Drew B., Leeuwenburgh C. (2002) Aging and the role of reactive nitrogen species. Ann. NY. Acad. Sci. 959:66-81.

22. Kroncke K.D. (2003) Nitrosative stress and transcription. Biol. Chem. 384:1365-1377.

23. Ridnour L.A., Thomas D.D., Mancardi D., Espey M.G., Miranda K.M., Paolocci N., Feelisch M., Fukuto J., Wink D.A. (2004) The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations. Biol. Chem. 385:1-10.

24. Calabrese V., Guagliano E., Sapienza M., Panebianco M., Calafato S., Puleo E., Pennisi G., Mancuso C., Butterfield D.A., Stella A.G. (2007) Redox regulation of cellular stress response in aging and neurodegenerative disorders: role of vitagenes. Neurochem. Res. 32:757-773.

25. Calabrese V., Boyd-Kimball D., Scapagnini G., Butterfield D.A. (2004) Nitric oxide and cellular stress response in brain aging and neurodegenerative disorders: the role of vitagenes. In Vivo 18:245-267.

26. Mancuso C., Scapagnini G., Curro D., Giuffrida Stella A.M., De Marco C., Butterfield D.A., Calabrese V. (2007) Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front. Biosci. 12:1107-1123.

27. Vina J., Borras C., Gomez-Cabrera M.C., Orr W.C. (2006) Part of the series: from dietary antioxidants to regulators in cellular signalling and gene expression. Role of reactive oxygen species and (phyto)oestrogens in the modulation of adaptive response to stress. Free Radic. Res. 40:111-119.

28. McCord J.M., Fridovich I. (1988) Superoxide dismutase: the first twenty years (1968-1988). Free Radic. Biol. Med. 5:363-369.

29. Calabrese E.J., Staudenmayer J.W., Stanek E.J. (2006) Drug development and hormesis: changing conceptual understanding of the dose response creates new challenges and opportunities for more effective drugs. Curr. Opin. Drug Discov. Devel. 9:117-123.

30. Zhang K., Kaufman R.J. (2006) The unfolded protein response: A stress signaling pathway critical for health and disease. Neurology 66:102-109.

31. Andersen J.K. (2004) Oxidative stress in neurodegeneration: cause or consequence? Nat. Med. 10:18-25.

32. Mancuso C., Perluigi M., Cini C., De Marco C., Giuffrida Stella A.M., Calabrese V. (2006) Heme oxygenase and cyclooxygenase in the central nervous system: a functional interplay. J. Neurosci. Res. 84:1385-1391.

33. Panahian N., Yoshiura M., Maines M.D. (1999) Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice. J. Neurochem. 72:1187-1203.

34. Takeda A., Perry G., Abraham N.G., Dwyer B.E., Kutty R.K., Laitinen J.T., Petersen R.B., Smith M.A. (2000) Overexpression of heme oxygenase in neuronal cells, the possible interaction with Tau. J. Biol. Chem. 275:5395-5399.

35. Premkumar D.R., Smith M.A., Richey P.L., Petersen R.B., Castellani R., Kutty R.K., Wiggert B., Perry G., Kalaria R.N. (1995) Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer’s disease. J. Neurochem. 65:1399-1402.

36. Schipper H.M. (2000) Heme oxygenase-1: role in brain aging and neurodegeneration. Exp. Gerontol. 35:821-830.

37. Mancuso C., Bates T.E., Butterfield D.A., Calafato S., Cornelius C., De Lorenzo A., Dinkova Kostova A.T., Calabrese V. (2007) Natural antioxidants in Alzheimer’s disease. Expert Opin. Investig. Drugs. 16:1921-1931.

38. Butterfield D., Castegna A., Pocernich C., Drake J., Scapagnini G., Calabrese V. (2002) Nutritional approaches to combat oxidative stress in Alzheimer’s disease. J. Nutr. Biochem. 13:444-461.

39. Scapagnini G., Colombrita C., Amadio M., D’Agata V., Arcelli E., Sapienza M., Quattrone A., Calabrese V. (2006) Curcumin activates defensive genes and protects neurons against oxidative stress. Antioxid. Redox. Signal. 8:395-403.

40. Ganguli M., Chandra V., Kamboh M.I., Johnston J.M., Dodge H.H., Thelma B.K., Juyal R.C., Pandav R., Belle S.H., DeKosky S.T. (2000) Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US Cross-National Dementia Study. Arch. Neurol. 57:824-830.

41. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21:8370-8377.

42. Wu L., Wang R. (2005) Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol. Rev. 57:585-630.

43. Kostoglou-Athanassiou I., Forsling M.L., Navarra P., Grossman A.B. (1996) Oxytocin release is inhibited by the generation of carbon monoxide from the rat hypothalamus--further evidence for carbon monoxide as a neuromodulator. Brain Res Mol. Brain Res. 42:301-306.

44. Mancuso C., Kostoglou-Athanassiou I., Forsling M.L., Grossman A.B., Preziosi P., Navarra P., Minotti G. (1997) Activation of heme oxygenase and consequent carbon monoxide formation inhibits the release of arginine vasopressin from rat hypothalamic explants. Molecular linkage between heme catabolism and neuroendocrine function. Brain Res. Mol. Brain Res. 50:267-276.

45. Mancuso C., Ragazzoni E., Tringali G., Liberale I., Preziosi P., Grossman A., Navarra P. (1999) Inhibition of heme oxygenase in the central nervous system potentiates endotoxin-induced vasopressin release in the rat. J. Neuroimmunol. 99:189-194.

46. Parkes D., Kasckow J., Vale W. (1994) Carbon monoxide modulates secretion of corticotropin-releasing factor from rat hypothalamic cell cultures. Brain Res. 646:315-318.

47. Yoo B.C., Seidl R., Cairns N., Lubec G. (1999) Heat-shock protein 70 levels in brain of patients with Down syndrome and Alzheimer’s disease. J. Neural. Transm. Suppl. 57:315-322

48. Morrison-Bogorad M., Zimmerman A.L., Pardue S. (1995) Heat-shock 70 messenger RNA levels in human brain: correlation with agonal fever. J. Neurochem. 64:235-246.

49. Kakimura J., Kitamura Y., Takata K., Umeki M., Suzuki S., Shibagaki K., Taniguchi T., Nomura Y., Gebicke-Haerter P.J., Smith M.A., Perry G., Shimohama S. (2002) Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J. 16:601-603.

50. Calabrese V., Testa G., Ravagna A., Bates T.E., Stella A.M. (2000) HSP70 induction in the brain following ethanol administration in the rat: regulation by glutathione redox state. Biochem Biophys. Res. Commun. 269:397-400.

51. Calabrese V., Bates T.E., Giuffrida Stella A.M. (2000) NO synthase and NOdependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance. Neurochem. Res. 65:1315-1341.

52. Yamawaki H., Haendeler J., Berk B.C. (2003) Thioredoxin: a key regulator of cardiovascular homeostasis. Circ. Res. 93:1029-1033.

53. Cho C.G., Kim H.J., Chung S.W., Jung K.J., Shim K.H., Yu B.P., Yodoi J., Chung H.Y. (2003) Modulation of glutathione and thioredoxin systems by calorie restriction during the aging process. Exp. Gerontol. 38:539-548.